Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2012

View Archived Issues

Scientists prepare new agents for urological disorders

Novel ddRNAi agents developed for hepatitis B

New immunomodulating fusion proteins presented by MIVAC Development

Tumor-targeting nanoparticle therapy shows promise in phase I testing

Taiho to kick off global phase III study RECOURSE

Peripheral blood monocyte biomarkers linked to emphysema

Allergic rhinitis drug reduces nasal symptoms in clinical trial

Bayer Schering Pharma divulges novel anticancer agents

U.S. team patents new DAP kinase 1 inhibitors and PPAR-gamma/GPR120 partial agonists

RELAX study assesses Botox in women with OAB

Clearance given for first-in-human trial of RXI-109

Viamet Pharmaceuticals discloses novel metalloenzyme inhibitors

Enrollment complete in pivotal CRUISE-1 study

Researchers at ProMetic Life Sciences report novel phenylketone carboxylates

GSK files for approval of eltrombopag for new indications

Dynamic Pharmaceuticals discovers new activators of pyruvate kinase isozyme M2

Primary endpoint met in phase IIb study of Visonac

Multiple-ascending-dose trial evaluates ARRY-502 pharmacokinetics

Treatment begins in study of Genelux's vaccinia-based oncolytic viral therapy

Eisai files application in Japan for Pariet triple-formulation pack

Omeros launches substudy in phase III OMS-302 program

Tau Therapeutics and NCI begin clinical study of Interlaced Therapy

Chelsea Therapeutics reports on preliminary analysis of phase II trial in RA

Bayer Yakuhin launches new granule formulation of Fosrenol in Japan

Oncothyreon commences phase I/II trial of PX-866 with Zelboraf

Pivotal TOWER trial meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...